Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom.
The introduction of routine infant immunization with Haemophilus influenzae type b (Hib) conjugate vaccines in the United Kingdom in 1992 led to a significant reduction in invasive disease due to this organism. Subsequently, between 1999 and 2003 there was an increase in the number of immunized children with Hib infection. We investigated whether the rise in cases was related to changes in anti-polyribosylribitol phosphate (PRP) antibody concentration or avidity. Using stored sera, we analyzed temporal changes in antibody levels among 3- to 5-year-old children immunized between 1991 and 2000. Anti-PRP antibody concentrations were higher in 3- to 5-year-olds who received infant immunization in 1991 than those in subsequent years. This difference may be related to changes in either the mode of administration of Hib conjugate vaccines or the rates of Hib nasopharyngeal carriage. This study emphasizes the factors affecting anti-PRP antibody concentration following immunization with conjugate vaccines and the importance of these in long-term protection from invasive disease.
Kelly
Dominic F
DF
Oxford Vaccine Group, Oxford University Department of Paediatrics, Oxford, United Kingdom. dominic.kelly@paediatrics.ox.ac.uk
Moxon
E Richard
ER
Yu
Ly-Mee
LM
Pollard
Andrew J
AJ
D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology*; D016667:Bacterial Capsules / Q000276:immunology; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D018073:Haemophilus Vaccines / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D007223:Infant; D011134:Polysaccharides / Q000276:immunology*; D006113:United Kingdom
D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011134:Polysaccharides; C008984:polyribitol phosphate
J Clin Invest. 1972 Jan;51(1):31-8
4536614
J Infect Dis. 1998 Apr;177(4):1112-5
9534995
Vaccine. 2000 Sep 15;19(2-3):367-75
10930692
Pediatr Infect Dis J. 1993 Jun;12(6):478-84
8345980
Commun Dis Public Health. 2003 Apr;6(1):55-8
12736974
N Engl J Med. 2006 Apr 6;354(14):1522-4
16598050
Expert Rev Vaccines. 2008 Feb;7(1):97-115
18251697
Epidemiol Infect. 2007 Jul;135(5):861-7
17092395
Pediatr Infect Dis J. 1991 Oct;10(10):764-71
1945579
Pediatrics. 1993 Dec;92(6):827-32
8233745
Vaccine. 1998 May-Jun;16(9-10):921-7
9682338
CMAJ. 1993 Oct 15;149(8):1105-12
8221449
Immunology. 2004 Oct;113(2):163-74
15379976
Epidemiol Infect. 2004 Aug;132(4):765-7
15310180
J Infect Dis. 1995 Jan;171(1):93-8
7798687
Vaccine. 2004 Jan 2;22(3-4):378-82
14670319
JAMA. 2005 Apr 13;293(14):1751-8
15827314
Pediatr Infect Dis J. 1994 May;13(5):348-55
8072815
Lancet. 2003 May 3;361(9368):1523-4
12737867
Infect Immun. 1998 May;66(5):2093-8
9573094
JAMA. 2000 Nov 8;284(18):2334-40
11066183
Lancet. 1999 Dec 11;354(9195):2063-8
10636384
Clin Infect Dis. 2008 Jan 15;46(2):186-92
18171249
J Pediatr. 1999 Feb;134(2):253-4
9931552
Pediatr Infect Dis J. 1998 Sep;17(9 Suppl):S117-22
9781743
Pediatr Infect Dis J. 1993 Aug;12(8):638-43
8414775
BMJ. 1992 Aug 29;305(6852):485-6
1392989
Emerg Infect Dis. 1996 Jul-Sep;2(3):176-82
8903227
JAMA. 1992 Mar 18;267(11):1489-94
1538539
Vaccine. 1997 Feb;15(2):149-54
9066031
Arch Dis Child. 1992 Apr;67(4):475-8
1580674
Arch Dis Child. 2003 May;88(5):379-83
12716702
BMJ. 2004 Sep 18;329(7467):655-8
15374916
Vaccine. 1995 Nov;13(16):1547-50
8578840
Pediatrics. 1995 Apr;95(4):522-7
7700752
Acta Paediatr. 2003 May;92(5):541-5
12839281
Clin Infect Dis. 2002 Jan 15;34(2):191-7
11740707
Lab Invest. 1979 Jun;40(6):678-85
312973
J Med Microbiol. 2006 Jul;55(Pt 7):887-896
16772416
Lancet. 2003 May 3;361(9368):1521-3
12737866
Arch Dis Child. 2007 Jan;92(1):11-6
16670121
Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S278-87
11709760